Printer Friendly

GLAXO DONATION TO FIGHT TB OUTBREAK IN U.S.

 GLAXO DONATION TO FIGHT TB OUTBREAK IN U.S.
 RESEARCH TRIANGLE PARK, N.C., April 29 /PRNewswire/ -- Glaxo Inc.


will donate 15,000 vials of a scarce antibiotic to help fight the nation's alarming increase in tuberculosis, the pharmaceutical company announced today.
 Glaxo Inc. will purchase the drug, streptomycin, from the worldwide Glaxo Group's Canadian subsidiary and donate it to the national Centers for Disease Control.
 The company's donation is in response to an appeal from the U.S. Food and Drug Administration for medicines effective against TB.
 "The gift from Glaxo is especially timely," said FDA Commissioner David Kessler, M.D. "We are delighted with their response."
 Streptomycin is not currently produced in the United States. Although formerly one of the frontline drugs for the treatment of tuberculosis, it has not been manufactured in large quantities in recent years because the disease was thought to be largely under control. Since 1984, however, the incidence of TB has been rising, jumping nearly 16 percent to almost 26,000 cases in 1990, according to the Centers for Disease Control.
 Especially vulnerable, experts say, are the homeless, whose poor nutrition, crowded shelters and lack of medical care contribute to the disease. Also at high risk are people infected with the AIDS virus, among whom the incidence of TB is 500 percent higher than in the general population.
 "It's tragic that a disease we thought was nearly eradicated has resurfaced to cause so much pain and suffering," said Charles A. Sanders, M.D., Glaxo Inc's. chairman and chief executive officer, who also is chairman of Glaxo Canada Inc.
 "Fortunately, we do have medicines that can fight the disease. The sooner TB victims can get effective treatments, the sooner this threat to the nation's health will be under control again."
 Glaxo Inc. already has donated 3,000 vials of streptomycin and will provide an additional 6,000 vials by the end of April. A subsequent shipment of another 6,000 vials is planned this summer.
 Glaxo Inc., headquartered in Research Triangle Park, N.C., researches, develops, manufactures and markets prescription medicines, including those for the treatment of gastrointestinal, respiratory, central nervous system, infectious, cardiovascular and dermatological diseases.
 -0- 4/29/92
 /CONTACT: Ramona Jones, Corporate Communications, Glaxo Inc., 919-248-2839/ CO: Glaxo Inc. ST: North Carolina IN: MTC SU:


CM -- CH005 -- 4203 04/29/92 09:17 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 29, 1992
Words:393
Previous Article:RIBI IMMUNOCHEM REPORTS 1992 FIRST-QUARTER FINANCIAL RESULTS
Next Article:WENDY'S PROFITS UP 30 PERCENT IN FIRST QUARTER


Related Articles
GLAXO ANNOUNCES INITIATIVE FOR BETTER TB MEDICINES
GlaxoSmithKline Welcomes the Settlement of Industry Association Litigation Against the South African Government.
Powder Ject bidding war turns full circle.
Farmer's cattle face slaughter amid TB fears; Island braced for fresh crisis after positive tests on herd.
Reaction to SARS outbreak may indirectly help TB suffers, WHO says.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters